Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Koiji SasakiHagop M KantarjianNicholas James ShortBachar SamraJoseph D KhouryRashmi Kanagal-ShamanaMarina KonoplevaNitin JainCourtney D D DiNardoRita KhouriGuillermo Garcia ManeroTapan Mahendra KadiaWilliam G WierdaIssa F KhouriPartow KebriaeiRohtesh S MehtaRichard E ChamplinRebecca GarrisCora Marie CheungNaval G DaverPhilip A ThompsonMusa YilmazFarhad RavandiElias J JabbourPublished in: Cancer (2021)
In patients with Ph-positive ALL, ponatinib is superior to other types of TKIs in inducing and maintaining a CMR, thus preventing disease progression. ASCT does not improve outcome once a 3-month CMR is achieved.